Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $25.00 by Analysts at HC Wainwright

Intellia Therapeutics (NASDAQ:NTLA) had its price objective reduced by research analysts at HC Wainwright from $30.00 to $25.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 78.70% from the company’s current price.

NTLA has been the subject of a number of other reports. Chardan Capital raised their price objective on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, April 27th. reissued a “buy” rating on shares of Intellia Therapeutics in a report on Tuesday, March 3rd. Sanford C. Bernstein reissued a “market perform” rating on shares of Intellia Therapeutics in a report on Wednesday. Wall Street Zen raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Citigroup reissued an “outperform” rating on shares of Intellia Therapeutics in a report on Tuesday, April 28th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Intellia Therapeutics has a consensus rating of “Hold” and an average target price of $20.14.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $13.99 on Wednesday. The company has a 50-day moving average of $13.67 and a 200-day moving average of $12.15. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -3.95 and a beta of 1.93. Intellia Therapeutics has a 52 week low of $6.83 and a 52 week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. The company had revenue of $15.05 million during the quarter, compared to the consensus estimate of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 55.63%. Sell-side analysts forecast that Intellia Therapeutics will post -3.5 EPS for the current year.

Institutional Investors Weigh In On Intellia Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. increased its position in Intellia Therapeutics by 36.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company’s stock valued at $46,000 after acquiring an additional 948 shares in the last quarter. Hollencrest Capital Management acquired a new stake in Intellia Therapeutics in the 1st quarter valued at about $49,000. Dimensional Fund Advisors LP increased its position in Intellia Therapeutics by 20.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,318,110 shares of the company’s stock valued at $29,709,000 after acquiring an additional 386,261 shares in the last quarter. Swiss National Bank increased its position in Intellia Therapeutics by 8.4% in the 1st quarter. Swiss National Bank now owns 217,800 shares of the company’s stock valued at $2,792,000 after acquiring an additional 16,800 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in Intellia Therapeutics by 11.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 19,240 shares of the company’s stock valued at $255,000 after acquiring an additional 1,990 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.